Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 3Breast 2Other neoplasm 1Other hematologic neoplasm 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 147Gastro-enteropancreatic neuroendocrine tumor 29Carcinoma, Neuroendocrine 18Neoplasms 16Breast Neoplasms 13Adenoma, Islet Cell 13Prostatic Neoplasms 11Carcinoma, Hepatocellular 11Carcinoid Tumor 11Stomach Neoplasms 10Pancreatic Neoplasms 10Colorectal Neoplasms 10Sarcoma 9Pheochromocytoma 9Thyroid Neoplasms 8Paraganglioma 8Neoplasm Metastasis 8Lung Neoplasms 8Cholangiocarcinoma 8Small Cell Lung Carcinoma 7Ovarian Neoplasms 7Melanoma 7Esophageal Neoplasms 7Anus Neoplasms 7Rectal Neoplasms 6Mesothelioma 6Colonic Neoplasms 6Carcinoma 6Brain Neoplasms 6Uterine Cervical Neoplasms 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypersensitivity × NET × 1 year × Clear all
NCT01673906 2025-06-24

68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours

Azienda USL Reggio Emilia - IRCCS

Phase 2 Completed
142 enrolled
EndocrineNET

Hypersensitivity, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡